Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

New CONCEPTT trial results show improved newborn health and more time-in-range in women with type 1 diabetes using CGM during pregnancy
Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits
Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA
A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide
FDA Approves New GLP-1 Label on Victoza to show that the medicine makes hearts healthier!
Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA
CANVAS study presented at ADA 2017 highlights heart and kidney protection for type 2 diabetes drug Invokana, and questions persist over an increased risk of amputations
The latest evidence on Saxenda shows that three years of treatment with the drug lowers risk for type 2 diabetes by an impressive 79%
Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba
CVD-REAL study showed SGLT-2 inhibitors reduce the risk of hospitalization for heart failure in over 300,000 people with type 2 diabetes
No fingersticks needed? Plus, a look at the “thinnest CGM ever” from Dexcom and Verily
less risk of diabetes complications, lower A1c, improved weight loss and hypoglycemia; led by Novo Nordisk’s Victoza and semaglutide
AADE’s Dr. Susan Guzman and diaTribe ’s Adam Brown discuss how common stigma is, why it matters, and tips to overcome it
Significant Improvement in A1c and time-in-range when adding CGM.
Highlights from the first study of a commercial automated insulin delivery device. Plus, Medtronic’s latest software updates!
Strong results from the IMPACT study in low-A1c users.
The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?
LEADER results announced at #2016ADA – compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease. More results...
People with type 2 diabetes should contact their physicians if they notice new pain, sores, or infections on their legs or feet.
JDRF and Helmsley Charitable Trust workshop highlights future goals and expectations for glucose-responsive insulin.

Pages